Allergic and non-allergic ovarian cancer patients treated with carboplatin or carboplatin desensitization presented a similar life expectancy with a non significant advantage for the allergy desensitized patients. A framework to rank genomic alterations as targets for cancer precision medicine.ESCAT scores for genomic alterations with actionable drug matches are now being gradually integrated into ESMO tumour-focused Clinical Practice Guidelines. (2010). Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ. Careers. ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. 20, 566573. The overall safety profile was similar between subgroups. The ESMO Clinical Practice Guidelines, prepared and reviewed by leading experts and based on the findings of evidence-based medicine, provide you with a set of recommendations to help patients with the best care options. Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. Multivariate analysis was conducted using logistic regression to estimate the association between the potential risk factors and the occurrence of hypersensitivity. However, basophil activation has been observed in patients with a history of severe carboplatin hypersensitivity reaction (Iwamoto et al., 2014). J Investig Allergol Clin Immunol. Integrating science into oncology for a better patient outcome, ESMO Designated Centres Community Session, Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the. doi: 10.3802/jgo.2013.24.4.342, Confino-Cohen, R., Fishman, A., Altaras, M., and Goldberg, A. Patients feel psycho-social impact of chemo m | EurekAlert! Clin Rev Allergy Immunol. Federal government websites often end in .gov or .mil. Gynecol. ESMO on Anemia, Iron Deficiency in Cancer Patients Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. 105, 8183. (2010) described the use of cisplatin as an alternative to carboplatin. Oncol. The histological type was serous in 381 patients (51.8%) and clear cell in 148 patients (20.1%). J. Gynecol. Epub 2017 Feb 24. Ke. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. All of these reported symptoms and signs occurred within an hour of initiating carboplatin administration. Characteristics of the 735 women receiving carboplatin-based chemotherapy. sharing sensitive information, make sure youre on a federal doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). Note: Approved by the ESMO Guidelines Committee: July 2017, last update October 2022. . Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Unable to load your collection due to an error, Unable to load your delegates due to an error. NCT00567190, NCT02402712, NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854, NCT03674112. Yamamoto A, Kamoi S, Matsuda S, Kawase R, Nakanishi K, Suzuki S. Medicines (Basel). Monitor. Vaccines (Basel). Platinum-based combination chemotherapy is the recommended treatment for platinum-sensitive recurrent ovarian cancer (Parmar et al., 2003; Pfisterer et al., 2006; Pujade-Lauraine et al., 2010). Incidence and intensity of anaphylaxis/hypersensitivity events: Table: 138P. Would you like email updates of new search results? Severe reactions are less frequent and may be fatal without appropriate intervention. Tx-nave pts ORR was 90%. eCollection 2022. Management of infusion reactions to systemic anticancer therapy: ESMO TABLE 3 Table 3. All funding for this site is provided directly by ESMO. Allergy Asthma Proc (2011) 32(1):79.10.2500/aap.2011.32.3409 (2003) reported that paclitaxel with platinum improves overall survival compared to conventional platinum-based chemotherapy among patients with relapsed platinum-sensitive ovarian cancer. 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. government site. The ESMOClinical Practice Guidelines(CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings ofevidence-based medicine. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). Front Oncol. The characteristics of the 735 patients are presented in Table 2. 329 (152 CPI-treated v 177 CPI-nave, including 60 tx-nave) pts with RET fusion+ NSCLC were analyzed. Blood. doi: 10.1111/j.1525-1438.2005.00136.x, Koshiba, H., Hosokawa, K., Kubo, A., Miyagi, Y., Oda, T., Miyagi, Y., et al. (1994). ESMO Clinical Practice Guidelines Provide your patients with the best care options Supporting your clinical decisions with ESMO's regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The .gov means its official. Oncol Res Treat. Abe et al. Lacouture, V. Sibaud, P.A. Management of toxicities from immunotherapy: ESMO Clinical Practice Before (2009). Gynecol. Necessary cookies enable core functionality. The results of the trial could answer whether carboplatin hypersensitivity patients have similar chemo-responses in non-platinum regimens without compromising the efficacy of the antineoplastic regimens of these patients. Merck: Driving Innovation in Cancer Care at ESMO 2017 With New Data in 'Allergy' is a hypersensitivity reaction (HSR) initiated by specic immunolo- gical mechanisms. Lacouture, V. Sibaud, P.A. An official website of the United States government. Annals of Oncology (2021) 32 (suppl_5): S407-S446. As shown in Table 6, drug or food history (odd ratios [OR] 2.340, 95% confidence interval [CI] 1.374-3.984, P = 0.0018), malignant ascites (OR 1.895, 95% CI 1.1083.241, P = 0.0196), and cumulative carboplatin dose (4,0004,999 mg: OR 5.507, 95% CI 1.79616.887, P = 0.0028; 5,0009,999 mg: OR 7.244, 95% CI 2.74019.149, P < 0.0001; 10,000 mg: OR 8.461, 95% CI 3.00723.806, P < 0.0001; P for trend < 0.0001) significantly positively correlated with carboplatin hypersensitivity. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population. ESMO Virtual Congress 2020 | OncologyPRO ESMO is a Swiss-registered not-for-profit organisation. Swain: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Advisory Role: Exact Sciences (Genomic Health); Financial Interests, Personal, Advisory Role: Molecular Templates; Financial Interests, Personal, Advisory Role: Silverback Therapeutics; Financial Interests, Personal, Advisory Role: Tocagen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Natera; Financial Interests, Personal, Advisory Role: Beijing Medical Foundation; Financial Interests, Personal, Advisory Board: Inivata; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Research Grant: KailosGenetics; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: BMS; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Lilly; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Daiichi-Sankyo; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Caris Life Sciences; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Tan: Non-Financial Interests, Institutional, Research Grant: Genentech/Roche; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Immunomedics; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Athenex; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Merck; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. L. Gianni: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: ADC Therapeutics; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Genentech, Inc.; Financial Interests, Personal, Advisory Board: Genomic Health; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Oncolytics Biotech; Financial Interests, Personal, Advisory Board: Odonate Therapeutics; Financial Interests, Personal, Advisory Board: Onkaido Therapeutics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Taiho Pharmaceutical; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Synthon and Zymeworks; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Zymeworks; Financial Interests, Institutional, Research Grant: Revolution Medicines; Financial Interests, Personal, Advisory Role: Forty Seven; Financial Interests, Personal, Advisory Role: Metis Precision Medicine; Financial Interests, Personal, Advisory Role: Menarini Ricerche; Financial Interests, Personal, Advisory Role: Synaffix; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Revolution Medicines; Non-Financial Interests, Personal, Other, Patent; EPA 12195182.6 12196177.5-Roche, pending (coinventor): Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Kmmel: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Personal, Advisory Role: Exact Science; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Daiichi Sanyko; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Somatex; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: PFM medical; Financial Interests, Personal, Advisory Role: Lily; Non-Financial Interests, Personal, Other: Roche; Non-Financial Interests, Personal, Other: Daiichi Sankyo; Non-Financial Interests, Personal, Other: Lily; Non-Financial Interests, Personal, Other: Sonoscape; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Dang: Financial Interests, Personal, Other, Honoraria: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Honoraria: Genentech, Inc.; Financial Interests, Personal, Other, Honoraria: Daiichi-Sankyo; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Puma Biotechnology; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Other, Travel expenses: Celgene; Financial Interests, Personal, Other, Travel expenses: Roche; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Celgene; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: MSD; Financial Interests, Personal, Other, Honoraria: Tesaro; Financial Interests, Personal, Other, Honoraria: Lily; Financial Interests, Personal, Other, Travel expenses: Pfizer; Financial Interests, Personal, Other, Honoraria: Seagen; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. J. O'Shaughnessy: Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: Agendia; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Genentech, Inc.; Financial Interests, Personal, Advisory Role: Immunomedics; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Odonate; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Puma; Financial Interests, Personal, Advisory Role: Prime Oncology; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Advisory Role: Seattle Genetics; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Aguila: Financial Interests, Personal, Full or part-time Employment, Clinical Scientist/Medical Director: F. Hoffmann-La Roche Ltd.; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Heeson: Financial Interests, Personal, Full or part-time Employment: Roche Products Ltd.; Financial Interests, Personal, Stocks/Shares: Roche Products Ltd.; Non-Financial Interests, Personal, Other, Patent; PH FDC SC: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Macharia: Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffman-La Roche.